Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins

6,633 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Advances in global change research require open science by individual researchers (2012, methodology): “…improve future experimental designs; not surprisingly, much research in the medical sciences has already D at a © 2012 Blackwell Publishing Ltd, Global Change Biology, 18, 2102–2110 switched to this method for meta-analyses (e.g., Alberti et al., 1995; Concato et al., 2000; Baigent et al., 2005).”
EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis (2009, background): “79 84 Similarly to statins, ACE inhibitors and angiotensin II (AT-II) blockers may also have a favourable effect on inflammatory markers and endothelial function in RA.”
The power of genetic diversity in genome-wide association studies of lipids (2021, methodology): “Individuals on cholesterol-lowering medication had their pre-medication levels 44 approximated by dividing the LDL-C value by 0.7 and the TC value by 0.8.”
[Guidelines on the management of stable angina pectoris: executive summary]. (2006, background): “Statin therapy should always be considered for patients with stable CAD and stable angina, based on their elevated level of risk and evidence of benefit of cholesterol lowering within the ‘normal’ range.(166) Therapy should aim at statin dosages documented to reduce morbidity/mortality in clinical t”